logo
Plus   Neg
Share
Email

Novartis To Initiate Proof Of Concept Study With Cosentyx - Quick Facts

Novartis (NVS) announced the plan to initiate ARROW, a head-to-head proof of concept study to assess the mechanistic superiority of the direct inhibition of IL-17A with Cosentyx (secukinumab) over the inhibition of IL-23 with Tremfya (guselkumab) in patients with psoriatic plaques resistant to treatment with Stelara. Study results are expected in 2019.

Cosentyx is the first fully-human biologic that specifically inhibits interleukin-17A (IL-17A), a cornerstone cytokine involved in the inflammation and development of psoriasis, ankylosing spondylitis, and psoriatic arthritis.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Starbucks Coffee Co. said Tuesday it is expanding its "Starbucks Delivers" pilot to an additional six cities across the U.S. The expansion of the delivery service, in partnership with Uber Eats, begins today in San Francisco, the first of six new markets to offer the service to customers. The coffee giant plans to bring Starbucks Delivers to nearly one-quarter of U.S. company-operated stores. The Port Authority of the Bay of Algeciras or APBA has signed an agreement to collaborate with Tradelens, a blockchain technology-based shipping platform, Europa News reported. Tradelens, which was launched in August last year, was jointly developed by IBM and Danish shipping giant Maersk, to bring transparency in the shipping industry. Johnson & Johnson (JNJ) Tuesday reported a profit for the fourth quarter, compared to a loss last year. The year-ago quarter's results included the impact of a hefty charge related to the U.S. tax reform. Quarterly sales increased 1.0% from the prior year. Both adjusted earnings per share and quarterly sales topped analysts' expectations.
Follow RTT